共查询到20条相似文献,搜索用时 46 毫秒
1.
Priscilla A. van Riet Djuna L. Cahen Katharina Biermann Bettina Hansen Alberto Larghi Guido Rindi Giovanni Fellegara Paolo Arcidiacono Claudio Doglioni Nicola Liberta Decarli Julio Iglesias‐Garcia Ihab Abdulkader Hector Lazare Iglesias Masayuki Kitano Takaaki Chikugo Satoru Yasukawa Hans van der Valk Nam Quoc Nguyen Andrew Ruszkiewicz Marc Giovannini Flora Poizat Schalk van der Merwe Tania Roskams Erwin Santo Silvia Marmor Kenneth Chang Fritz Lin James Farrell Marie Robert Juan Carlos Bucobo Alan Heimann Francisco Baldaque‐Silva Carlos Fernndez Moro Marco J. Bruno 《Digestive endoscopy》2019,31(6):690-697
2.
The anti‐lymphoma activity of antiviral therapy in HCV‐associated B‐cell non‐Hodgkin lymphomas: a meta‐analysis 下载免费PDF全文
J. Peveling‐Oberhag L. Arcaini K. Bankov S. Zeuzem E. Herrmann 《Journal of viral hepatitis》2016,23(7):536-544
Many epidemiological studies provide solid evidence for an association of chronic hepatitis C virus (HCV) infection with B‐cell non‐Hodgkin's lymphoma (B‐NHL). However, the most convincing evidence for a causal relationship between HCV infection and lymphoma development is the observation of B‐NHL regression after HCV eradication by antiviral therapy (AVT). We conducted a literature search to identify studies that included patients with HCV‐associated B‐NHL (HCV‐NHL) who received AVT, with the intention to treat lymphoma and viral disease at the same time. The primary end point was the correlation of sustained virological response (SVR) under AVT with lymphoma response. Secondary end points were overall lymphoma response rates and HCV‐NHL response in correlation with lymphoma subtypes. We included 20 studies that evaluated the efficacy of AVT in HCV‐NHL (n = 254 patients). Overall lymphoma response rate through AVT was 73% [95%>confidence interval, (CI) 67–78%]. Throughout studies there was a strong association between SVR and lymphoma response (83% response rate, 95%>CI, 76–88%) compared to a failure in achieving SVR (53% response rate, 95%>CI, 39–67%, P = 0.0002). There was a trend towards favourable response for AVT in HCV‐associated marginal zone lymphomas (response rate 81%, 95%>CI, 74–87%) compared to nonmarginal zone origin (response rate 71%, 95%>CI, 61–79%, P = 0.07). In conclusion, in the current meta‐analysis, the overall response rate of HCV‐NHL under AVT justifies the recommendation for AVT as first‐line treatment in patients who do not need immediate conventional treatment. The strong correlation of SVR and lymphoma regression supports the hypothesis of a causal relationship of HCV and lymphomagenesis. 相似文献
3.
4.
Takahisa Hirose Takeshi Ogihara Shusaku Tozaka Sami Kanderian Hirotaka Watada 《Journal of diabetes investigation.》2013,4(3):287-296
Aims/Introduction
Many patients with diabetes now use 5‐, 6‐ or 8‐mm needles for insulin injection. However, it is unclear whether needle length, particularly for shorter needles, affects the pharmacokinetic properties of insulin.Materials and Methods
This was a three‐way, randomized, cross‐over, single‐center study involving 12 healthy Japanese adult males (age 27.4 ± 4.14 years; weight 64.2 ± 5.2 kg; body fat percentage 18.2 ± 1.5%). Participants received a subcutaneous (abdomen) dose of insulin lispro (1.5 U for participants weighing 55 to <65.0 kg; 2.0 U for participants weighing 65.0 to <80.0 kg) delivered using a 32‐G × 4 mm (32G × 4), 31‐G × 8 mm (31G × 8) or 32‐G × 6 mm (32G × 6) needle with a 3–7‐day washout between doses. Pharmacokinetic parameters of exogenous insulin were identified using non‐linear least squares, where the total insulin concentration was fit to the measured plasma insulin concentration using an overall combined model that accounted for C‐peptide/insulin secretion in addition to the injected dose.Results
Maximum concentration and area under the curve for 0 to infinity min for insulin were bioequivalent for the 32G × 4 needle relative to the 32G × 6 and the 31G × 8 needles. The time to the maximum insulin concentration was bioequivalent for the 32G × 4 needle relative to the 32G × 6 needle, but not the 31G × 8 needle.Conclusions
The use of 4‐mm needles is unlikely to change the pharmacokinetic properties of insulin when injected subcutaneously in adults. This trial was registered with UMIN‐CTR (no. UMIN000004469). 相似文献5.
6.
7.
8.
Comparative analysis between RQ‐PCR and digital‐droplet‐PCR of immunoglobulin/T‐cell receptor gene rearrangements to monitor minimal residual disease in acute lymphoblastic leukaemia 下载免费PDF全文
Irene Della Starza Vittorio Nunes Marzia Cavalli Lucia Anna De Novi Caterina Ilari Valerio Apicella Antonella Vitale Anna Maria Testi Ilaria Del Giudice Sabina Chiaretti Robin Foà Anna Guarini 《British journal of haematology》2016,174(4):541-549
Real‐time quantitative polymerase chain reaction (RQ‐PCR) is a standardized tool for minimal residual disease (MRD) monitoring in acute lymphoblastic leukaemia (ALL). The applicability of this technology is limited by the need of a standard curve based on diagnostic DNA. The digital droplet PCR (ddPCR) technology has been recently applied to various medical fields, but its use in MRD monitoring is under investigation. In this study, we analysed 50 ALL cases by both methods in two phases: in the first, we established analytical parameters to investigate the applicability of this new technique; in the second, we analysed MRD levels in 141 follow‐up (FU) samples to investigate the possible use of ddPCR for MRD monitoring in ALL patients. We documented that ddPCR has sensitivity and accuracy at least comparable to those of RQ‐PCR. Overall, the two methods gave concordant results in 124 of the 141 analysed MRD samples (88%, P = 0·94). Discordant results were found in 12% borderline cases. The results obtained prove that ddPCR is a reliable method for MRD monitoring in ALL, with the advantage of quantifying without the need of the calibration curves. Its application in a cohort of patients with a longer FU will conclusively define its clinical predictive value. 相似文献
9.
Recent studies have associated genetic variation near the interleukin 28B (IL28B/IFN‐λ3) gene with natural clearance of the hepatitis C virus (HCV) infection, and a common variant in the DEP domain containing 5 (DEPDC5) locus on chromosome 22 has been shown to affect susceptibility to hepatocellular carcinoma (HCC) in Japanese individuals with chronic HCV infection. This study was conducted to determine whether polymorphisms near or in interferon‐lambda (IFN‐λs) genes and their receptor genes such as interleukin 28 receptor, alpha (IL28RA) and interleukin 10 receptor, beta (IL10RB) as well as p21_activated kinases 4 (PAK4) and iron/zinc purple acid phosphatase‐like protein (PAPL), which are locate upstream of IFN‐λs, and lastly the DEPDC5 gene are associated with hepatitis B virus‐related liver disease in Han Chinese. The study subjects included 507 normal healthy controls, 350 individuals with natural clearance of HBV and 792 HBV‐infected patients. The patients were categorized into 157 inactive carriers (Case I), 216 active carriers (Case II), 111 cirrhotics (Case III) and 308 HCC patients (Case IV) subgroups. Seven single nucleotide polymorphisms (SNPs) were genotyped using the Matrix‐assisted Laser Desorption/Ionisation mass spectrometric (MALDI‐TOF MS) SNP genotyping assay. Rs423058 upstream of PAPL, rs2834167 in IL10RB and rs1012068 in DEPDC5 were associated with chronic HBV status, HBV natural clearance and the presence of HCC (P = 0.0004–0.024), respectively. PAPL, IL10RB and DEPDC5 polymorphisms have an impact on progression of HBV‐related liver disease. However, IFN‐λs genes as a tool to differentiate between different clinical courses of HBV infection were not useful in the Han Chinese population. 相似文献
10.
11.
Interventions to significantly improve service uptake and retention of HIV‐positive pregnant women and HIV‐exposed infants along the prevention of mother‐to‐child transmission continuum of care: systematic review 下载免费PDF全文
Alexandra C. Vrazo Jacqueline Firth Anouk Amzel Rebecca Sedillo Julia Ryan B. Ryan Phelps 《Tropical medicine & international health : TM & IH》2018,23(2):136-148
12.
Mario Luppi Ivana Lagreca Patrizia Barozzi Chiara Quadrelli Daniela Vallerini Eleonora Zanetti Sabrina Basso Fabio Forghieri Monica Morselli Monica Maccaferri Ambra Paolini Valeria Fantuzzi Andrea Messerotti Rossana Maffei Ilaria Iacobucci Giovanni Martinelli Roberto Marasca Franco Narni Patrizia Comoli Leonardo Potenza 《British journal of haematology》2014,164(2):299-302
13.
Nirav N. Shah Aniko Szabo Scott F. Huntington Narendranath Epperla Nishitha Reddy Siddhartha Ganguly Julie Vose Cynthia Obiozor Fahad Faruqi Alexandra E. Kovach Luciano J. Costa Ana C. Xavier Ryan Okal Abraham S. Kanate Nilanjan Ghosh Mohamed A. Kharfan‐Dabaja Lauren Strelec Mehdi Hamadani Timothy S. Fenske Oscar Calzada Jonathon B. Cohen Julio Chavez Jakub Svoboda 《British journal of haematology》2018,180(4):534-544
Primary mediastinal (thymic) large B‐cell lymphoma (PMBCL) is an uncommon subtype of non‐Hodgkin lymphoma (NHL) that presents with a mediastinal mass and has unique clinicopathological features. Historically, patients with PMBCL were treated with R‐CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy ± involved field radiation. Since a phase II trial, published in April 2013, demonstrated excellent results using dose‐adjusted (DA) R‐EPOCH (rituximab, etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin), this treatment has gained popularity. We performed a retrospective, multicentre analysis of patients aged ≥18 years with PMBCL since January 2011. Patients were stratified by frontline regimen, R‐CHOP versus DA‐R‐EPOCH. 132 patients were identified from 11 contributing centres (56 R‐CHOP and 76 DA‐R‐EPOCH). The primary outcome was overall survival. Secondary outcomes included progression‐free survival, complete response (CR) rate, and rates of treatment‐related complications. Demographic characteristics were similar in both groups. DA‐R‐EPOCH use increased after April 2013 (79% vs. 45%, P < 0·001), and there was less radiation use after DA‐R‐EPOCH (13% vs. 59%, P < 0·001). While CR rates were higher with DA‐R‐EPOCH (84% vs. 70%, P = 0·046), these patients were more likely to experience treatment‐related toxicities. At 2 years, 89% of R‐CHOP patients and 91% of DA‐R‐EPOCH patients were alive. To our knowledge, this represents the largest series comparing outcomes of R‐CHOP to DA‐R‐EPOCH for PMBCL. 相似文献
14.
Low‐density lipoprotein and other predictors of response with telaprevir‐based therapy in treatment‐experienced HCV genotype 1 patients: REALIZE study 下载免费PDF全文
Thomas Berg Pietro Andreone Stanislas Pol Stuart Roberts Zobair Younossi Moises Diago Eric J. Lawitz Roberto Focaccia Graham R. Foster Andrzej Horban Isabelle Lonjon‐Domanec Ralph DeMasi Gaston Picchio Donghan Luo Sandra De Meyer Stefan Zeuzem 《Liver international》2015,35(2):448-454
15.
P. Pradat M.‐A. Le Pogam J.‐B. Okon P. Trolliet P. Miailhes C. Brochier M. Maynard F. Bailly F. Zoulim L. Cotte 《Journal of viral hepatitis》2013,20(9):650-657
We aimed to compare the evolution of estimated glomerular filtration rate (eGFR) in HIV‐, HIV–HBV‐ and HBV‐infected patients treated with tenofovir disoproxil fumarate (TDF). Three groups of patients receiving TDF > 12 months were recruited: 194 HIV‐infected patients, 85 HIV–HBV‐coinfected patients and 50 HBV‐infected patients. eGFR was estimated using the Modification of the Diet in Renal Disease (MDRD) equation. Multivariate regression models were constructed to estimate factors associated with eGFR decrease from baseline. A total of 329 patients were studied. Median follow‐up was 2.7 years. Median eGFR decrease was ?4.9 (?16.6 to +7.2) mL/min/1.73 m2. After multivariate stepwise regression analysis, age (P = 0.0002), non‐African origin (P < 0.0001), baseline eGFR (P < 0.0001) and TDF duration (P = 0.02) were associated with eGFR decrease in the whole population, while hypertension, diabetes and type of infection were not. Age (P < 0.0001), non‐African origin (P = 0.0004), baseline eGFR (P < 0.0001) and TDF duration (P = 0.007) remained associated with eGFR decline in HIV and HIV–HBV‐infected patients, while other variables including HIV risk factor, CDC stage, CD4 and HIV‐RNA levels were not. Age (P = 0.03), non‐African origin (P = 0.004), baseline eGFR (P < 0.0001) and baseline HBV–DNA > 2000 IU/mL (P = 0.04) were associated with eGFR decline in HBV and HIV–HBV‐infected patients, while other variables including HBV risk factor and fibrosis stage were not. Estimated glomerular filtration rate decline under TDF therapy appears mainly associated with older age, non‐African origin, higher baseline eGFR and longer TDF administration but not with the type of viral infection. Regular follow‐up of renal function, especially tubular function is recommended during TDF therapy. 相似文献
16.
Neutrophil‐To‐Lymphocyte Ratio: An Emerging Marker Predicting Prognosis in Elderly Adults with Community‐Acquired Pneumonia 下载免费PDF全文
Emanuela Cataudella MD Chiara M. Giraffa MD Salvatore Di Marca MD Alfredo Pulvirenti PhD Salvatore Alaimo PhD Marcella Pisano MD Valentina Terranova MD Thea Corriere MD Maria L. Ronsisvalle MD Rosario Di Quattro MD Benedetta Stancanelli MD PhD Mauro Giordano MD Carlo Vancheri MD PhD Lorenzo Malatino MD 《Journal of the American Geriatrics Society》2017,65(8):1796-1801
17.
18.
Benjamin Heidrich Beatriz C. Serrano Ramazan Idilman Gökhan Kabaçam Birgit Bremer Regina Raupach Fatih O. Önder Katja Deterding Behrend J. Zacher Andrzej Taranta Hakan Bozkaya Kalliopi Zachou Hans L. Tillmann Abdurrahman M. Bozdayi Michael P. Manns Cihan Yurdaydın Heiner Wedemeyer 《Liver international》2012,32(9):1415-1425
19.
20.
Post‐transplantation cyclophosphamide versus conventional graft‐versus‐host disease prophylaxis in mismatched unrelated donor haematopoietic cell transplantation 下载免费PDF全文
Rohtesh S. Mehta Rima M. Saliba Julianne Chen Gabriela Rondon Aimee E. Hammerstrom Amin Alousi Muzaffar Qazilbash Qaiser Bashir Sairah Ahmed Uday Popat Chitra Hosing Issa Khouri Elizabeth J. Shpall Richard E. Champlin Stefan O. Ciurea 《British journal of haematology》2016,173(3):444-455
Post‐transplantation cyclophosphamide (PTCy) is an effective strategy to prevent graft‐versus‐host disease (GVHD) after haploidentical haematopoietic cell transplantation (HCT). We determined the efficacy of PTCy‐based GVHD prophylaxis in human leucocyte antigen (HLA)‐mismatched unrelated donor (MMUD) HCT. We analysed 113 adult patients with high‐risk haematological malignancies who underwent one‐antigen MMUD transplantation between 2009 and 2013. Of these, 41 patients received PTCy, tacrolimus and mycophenolate mofetil (MMF) for GVHD prophylaxis; 72 patients received conventional prophylaxis with anti‐thymocyte globulin, tacrolimus and methotrexate. Graft source was primarily bone marrow (83% PTCy vs. 63% conventional group). Incidence of grade II–IV (37% vs. 36%, P = 0·8) and grade III–IV (17% vs. 12%, P = 0·5) acute GVHD was similar at day 100. However, the incidence of grade II‐IV acute GVHD by day 30 was significantly lower in the PTCy group (0% vs. 15%, P = 0·01). Median time to neutrophil (18 days vs. 12 days, P < 0·001) and platelet (25·5 days vs. 18 days, P = 0·05) engraftment was prolonged in PTCy group. Rates of graft failure, chronic GVHD, 2‐year non‐relapse mortality, relapse, progression‐free survival or overall survival were similar. Our results demonstrate that PTCy, tacrolimus and MMF for GVHD prophylaxis is safe and produced similar results as conventional prophylaxis in patients with one antigen HLA‐MMUD HCT. 相似文献